Literature DB >> 18240239

The orchestra of Toll-like receptors and their potential role in frequently occurring rheumatic conditions.

Mieke F Roelofs1, Shahla Abdollahi-Roodsaz, Leo A B Joosten, Wim B van den Berg, Timothy R D J Radstake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18240239     DOI： 10.1002/art.23217

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  6 in total

Review 1.  Helminth-derived immunomodulators: can understanding the worm produce the pill?

Authors:  William Harnett; Margaret M Harnett
Journal:  Nat Rev Immunol       Date:  2010-03-12       Impact factor: 53.106

Review 2.  Toll-like receptor polymorphisms and rheumatoid arthritis: a systematic review.

Authors:  Young Ho Lee; Sang-Cheol Bae; Jae-Hoon Kim; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2013-01-17       Impact factor: 2.631

Review 3.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

4.  Neutrophil hyperchemotaxis in Behçet's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses.

Authors:  Fabricio Souza Neves; Solange Carrasco; Cláudia Goldenstein-Schainberg; Célio Roberto Gonçalves; Suzana Beatriz Veríssimo de Mello
Journal:  Clin Rheumatol       Date:  2009-08-25       Impact factor: 2.980

Review 5.  Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.

Authors:  Kumar Vijay
Journal:  Int Immunopharmacol       Date:  2018-05-04       Impact factor: 4.932

6.  The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes.

Authors:  Timothy R D J Radstake; Lenny van Bon; Jasper Broen; Anila Hussiani; Roger Hesselstrand; Dirk M Wuttge; Yanhui Deng; Robbert Simms; Erik Lubberts; Robert Lafyatis
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.